were not part of the original caspase analysis, and were included here to support the association between pSTAT1 levels and activation of the caspase pathway. F. Caspase 9 and APAF1 levels (arrow marks APAF1 band) are not correlated with pSTAT1 levels or with cytotoxic response to MEK inhibition. G. Levels of known caspase inhibitors are not correlated with the cytotoxic phenotype or pSTAT1 levels. STAT pathway in two cell lines (SkMel105 -high pSTAT1, A375 -low pSTAT1). Most proteins don't change, although pSTAT1 goes up prior to 8h. Change of PIAS1 is similar in both cell lines. B. IFN genes with a significant differential expression between lowand high-pSTAT1 cell lines. IFNA6, IFNA8 and IFNB1 are located in the interferon locus (see figure 7) . C. Conditioned media experiment shows that SkMel105, a high-pSTAT1 cell line, releases cytokines to the media that lead to the upregulation of pSTAT1. In this experiment, SkMel105 was cultured for 24h, and then the media was transferred to A375, a low-pSTAT1 cell line. Cells were collected 30m and 1h following media transfer.
Lanes for MEK inhibition 8h and self-conditioned media (CM-A375) are shown as controls. CTBP2  LDLRAP1  C14orf104  GSK3B  SLC20A2  HERC1  ZNF275  C5orf22  ADSS  TTC15  C8orf55  CREBL2  WDR75  DNAJC3  TRIM65  UBAC1  BAG5  SETD4  SSBP4  BTBD10  LYSMD2  CHD2  TMEM206  ANKRD54  SRXN1  GOT1  ZFAND1  IL16  RCC1  PPM1A  WDR74  CBFA2T2  JMJD4  C19orf12  MTHFD2  KDM4A  WDR89  RCBTB1  NOB1  HOMER3  ANKRD37  SNX30  ZBTB42  WDHD1  ACTR3B  FEM1B  PSMG4  MTMR10  LENG9  AKAP11  NR6A1  BCORL1  PAX3  ABTB1  ABR  FNBP1L  CNPPD1  ZZZ3  GNA13  PEAK1  Table S1 -List of genes from figure 2A Gene symbols of the genes from figure 2A. The correlation of these genes with MITF levels is reveled only upon MEK inhibition. 
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Supplementary information
Microarray preprocessing
Samples for microarrays were harvested 8h post treatment. RNA was extracted using a Qiagen RNeasy kit, and labeled using Agilent's one-color labeling protocol. Labeled cRNA was hybridized to Agilent's 8x60 human gene expression arrays (expect for Colo829 and SkMel28 that were added to the panel after the first batch). MEK inhibition and basal state expression levels were measured in biological duplicates. Data normalization is described in supplementary material. Genatomy was used for data visualization and enrichment analysis (Litvin et al., 2009 ). Additionally, the Agilent probe flags were used to filter probes by a similar method:
probes flagged in more than 20% of samples were removed. Flags that were used:
will_above_bg, is_saturated, is_feat_non_uniform, is_feat_popn.
A "rescue" step was used to return probes representing genes that no probe was left to represent them. Probes representing the same gene with a high correlation (Pearson >0.75) were rescued. Additionally, probes with high SD (>3) were also rescued.
Data normalization
The 75th percentile of all samples was set to the average 75% by multiplying the values by a constant.
Probe averaging
Probes that measure the level of the same gene were averaged or filtered out.
If the average Pearson correlation between all probes is > .75, probes are averaged. If it is lower, the probe with the lowest correlation is removed. Process repeats till probes are averaged or only two probes are left. If only two probes left and the correlation is low, the probe with the higher raw intensity is chosen.
Merging duplicates
Baseline expression levels are mean-normalized at the gene level. Fold change is calculated against the control (baseline expression) of the cell line. Data from the two MEKi panels are combined at this point by averaging the baseline expression and fold change data.
COSPER -Context-Specific Regulation
COSPER -COntext SPEcific Regulation -is designed to identify genes that are directly regulated by the MAPK pathway (or any other perturbed pathway) in only a subset of cell lines. It is based on the assumption that genes under the direct control of a pathway are correlated before pathway inhibition and show a correlated expression change after pathway inhibition. Since we are looking for genes under the control of the pathway in only a subset of cell lines, we expect expression changes in only these cell lines.
COSPER uses pre-perturbation data to limit the search for genes under direct regulation of the perturbed pathway. After inhibition of a key signaling pathway such as MAPK, cellular events, such as metabolism, cell cycle and apoptosis, lead to expression changes of thousands of genes. Although the expression of those genes changes after MAPK inhibition, they are not directly regulated by MAPK. However, genes under the direct control of MAPK pathway depend on its activation levels both before and after inhibition of the pathway. For example, HEY1 ( figure 3A ) is under the control of MAPK in only a subset of cell lines. In HEY1 case, it is overexpressed by MAPK in cell lines with high MITF levels. Therefore, only in MITF-high cell lines, HEY1 expression levels decrease after MEK inhibition. Both pre-and post-inhibition expression levels are needed in order to determine this relationship.
COSPER is therefore designed to find genes with context-specific regulation patterns (figure 3B). It is consists of 3 major steps:
1. Gene level -identify binary splits with high scores for both baseline expression and fold change and construct clusters.
2. Merge related clusters -allows removal of spurious correlations and averaging the noise caused due to the small sample size.
Add high scoring genes to the remaining clusters
A detailed description of each of the steps follows the section on the NormalGamma score.
NormalGamma score
The algorithm is based on the NormalGamma score (DeGroot, 2004; Segal et al., 2003) .
The NormalGamma is a Bayesian score that takes variance, mean and number of data points into account. It gives a higher score to a data matrix with low variance.
We use this score since we are looking to reduce the variance of the samples. Our algorithm searches for genes that behave similarly in a subset of samples. For example,
we are looking for a subset of samples where a predefined set of genes is up-regulated, compared with the rest of the samples where the genes are not under pathway control.
Mathematically, this problem can be viewed as a subset of samples where the data have a lower variance compared with the variance of all samples combined. The
NormalGamma score is driven mainly by data variance and is thus suitable for our needs.
The score:
The score used to assess the quality of the split is:
Step 1: Creating clusters First, genes with low fold change and/or low variance in steady state are removed.
Genes were considered only if they changed by more than 0.7 fold change (log2 scale)
in at least 1 cell line, and at a steady-state expression value of 0.4 in at least 2 samples (to remove genes with extreme outliers in one sample that pass a standard-deviation based threshold). Additionally, all long non-coding RNA transcripts were removed. 5391
genes remain for further analysis.
Then, gene expression is normalized. Basal expression levels of each gene are set to have =0 and  =1. Fold change for each gene is standardized only ( =1).
Next, clusters are built bottom-up -genes are assigned to "splits", and a split with more than one gene assigned to it is considered a cluster. However, in order to filter out spurious associations we only consider clusters with 5 or more genes. All genes are tested across all valid binary splits. A valid split assigns at least 2 samples to each sample group. The test is based on permutations and the NormalGamma score.
A gene is assigned to a split if its NormalGamma scores (as defined in the previous section) in both the baseline expression and fold change are better than 99% of the split permutations (pvalue<0.01). Additionally, in order to keep the best split-gene pairs only, an additional threshold is used:
To determine whether clusters with more than 5 genes can be constructed by chance.
We permuted the samples in the fold change expression data and performed this step on the permutated data. No clusters with 5 or more genes were constructed. Hence we believe the resulting clusters represent biological phenomenon.
Step 2: Merging clusters
A gene assigned to a split is very likely to be assigned to similar splits. A similar split might have one or more samples switching "sides" ( figure 4A ). Each split has 13 similar splits with a distance=1, where one sample has switched sides, and 91 splits with distance=2.
The NormalGamma score is not strong enough to discriminate between the "true" split and neighboring splits, since the distribution of scores is very tight. However, we can assume that a gene is more likely to be assigned to the real biological split, and less likely to be associated with a split with a distance>0 from the real split. We also work under the assumption that a true biological "context" is likely to influence many genes, and therefore larger clusters are more biologically relevant.
We use these two assumptions in order to identify the real gene-split associations and remove irrelevant clusters.
The cluster merging algorithm is a iterative process. Each cycle identifies the largest cluster, its genes are removed from all its neighboring clusters, and the process iterates till no more clusters can be identified.
The steps are:
1. Each cluster is scored based on its overlap with its neighbors:
we used d=2.
2. We then choose the largest cluster, and remove its genes from all clusters with a distance<=d.
To save computing time, only clusters that enter the algorithm with 5 or more genes are allowed to be selected.
Step 3: Adding genes to remaining clusters
In the last step, after filtering most clusters out, we relax the statistical thresholds and add genes to the clusters (see Litvin et al 2009) . We found this step to be necessary due to the small sample size, and the relatively high noise of gene expression data.
The thresholds used in this step are: 
Perturbation reveals patterns hidden in pre-perturbation data
To identify genes that are correlated only post-but not pre-perturbation we used a method similar to step 1 in COSPER. Specifically, we searched for clusters that show the behavior depicted in figure 2B , by associating genes to clusters only if they have a good score in post-perturbation data, but a bad score in steady state data.
We used stringent thresholds to define "good" and "bad" scores. The good score was defined as a permutation-based NormalGamma score < 0.01, and a bad score was with a permutation p-value > 0.5. Additionally, we require that a gene will be associated only if the post-perturbation NormalGamma score will demonstrate:
While the pre-perturbation score will be:
To remove spurious associations, we only considered clusters with > 20 genes. Overall, 3941 genes were associated with one or more clusters. As an example to this behavior,
we show one such cluster in figure 2A .
COSPER results on steady-state or post-inhibition data alone
Combining pre-and post-inhibition data facilitates the identification of context-specific regulation and differential activation of pathways, while pre-inhibition data or steady state data alone fall short due to lower specificity and sensitivity.
We ran COSPER on each data set alone (pre or post inhibition). The number of modules increases dramatically, to 2684 with steady state data, and 1524 with post-inhibition data, compared with only 70 when using both data sets. Specificity is lost and those The combination of pre-and post-inhibition data, therefore, provides specificity and limits the cluster genes to only genes directly regulated by MAPK, while also provides the context of regulation.
Comparison of BRAF and MEK inhibition -PLX4720 vs. PD901
We used PD901 to inhibit the MAPK pathway, and not the more clinically used PLX4720
BRAF-V600E inhibitor to allow a direct comparison of BRAF and NRAS mutant cell lines.
To ensure the short-term drug effects are similar, we compared the transcriptional response of MalMe3M, a BRAF-V600E cell line, following PD901 or PLX4720 treatment.
We assessed expression fold change at 1 hour, 2, 4, and 8 hours following treatment using Illumina HumanHT-12 microarrays.
Preprocessing
Illumina's probe pvalues were used to filter out probes. Probes with p-value>0.05 in more than half of the samples were removed. Then microarrays were normalized according to their 75% percentile values. The 2 control array were averaged, and treated samples were compared to the averaged control to assess fold change.
Results
MEKi and BRAFi are remarkably the same at all time points. Although some probes were noisy, resulting in minor difference between treatments, no gene had a difference greater than 0.5 fold (on a log2 scale) between treatments at all time points. Only 6 probes, out of 16000, had a difference of more than 1 fold at 8 hour time point (figure S1B). None of them had such difference at 4 hours, suggesting that the difference arises from measurement noise.
We conclude that there is no difference in the short-time transcriptional response between treatments in this cell lines.
Comparison of the response to MEK inhibition between known genetic contexts
Both inactivation of PTEN and the type of MAPK activation (BRAF or NRAS) have been previously associated with the response to MAPK pathway inhibition. We examined whether these mutations are correlated with the transcriptional response to MEK inhibition or the basal expression levels prior to MEK inhibition.
We used t-test to compare the expression levels between BRAF-and NRAS mutant cell lines (figure S2A), and between PTEN-null and PTEN-wild type cell lines ( figure S2B ). In both cases we found that no genes are associated with those genetic contexts (FDR qvalue < 0.05), either before of after pathway inhibition.
PD901 and IFN microarray results
Data Preprocessing
Six cell lines were chosen for analysis. 3 are low-pSTAT1 -A375, SkMel133 and SkMel2, and 3 high-pSTAT1 -SkMel105, SkMel39 and WM1361. They were treated with 50nM PD901, 1000U/mL IFN or their combination. Samples were collected 8 hours after treatment, control samples were collected at 0h. RNA extraction, labeling and hybridization were conducted as described under methods. Agilent human 8x60 gene expression arrays were used.
Raw data normalization and filtering were conducted as described above, with a low threshold of 7, and an upper threshold of 17.5.
IFN response in high-vs. low-pSTAT1 cell lines
The IFN response includes dozens of genes with a dramatic induction in gene expression, of up to 500 fold, in all 6 cell lines ( figure S5B ).
There is, however, a difference in the extent of change in high-vs. low-pSTAT1 cell lines, that can be attributed to the different basal expression level of those genes (data not shown). The maximum level of expression seems to be similar in all cell lines, but high pSTAT1 cell lines have a higher basal activity and therefore the fold change is lower.
In order to compare the activation of the pathway between the two cell line groups, it is better to use the final expression level, i.e. the basal expression+fold change. However, such comparison reveals the expression of no genes is statistically significant different between high-and low-pSTAT1 cell lines (using t-test and FDR correction).
We therefore determine that there is no difference in the response to IFN between high-and low-pSTAT1 cell lines.
Combinatorial treatment and synergy
To test whether the MEK inhibition and IFN synergize at the level of gene expression, we compared the fold change of the dual treatment with that of MEKi+IFN as single agents. Over all, those responses are very similar ( figure S5C ).
If no synergy exists, the values of Both-(MEKi+IFN) should be close to 0. Only one gene significantly deviates from 0 in all 6 cell lines. The gene is CCL4, and it is induced both by MEKi and IFN treatment as single agents, but a combinatorial treatment isn't additive.
We couldn't identify any other genes that show a synergetic response in all 6 cell lines, or separately in low-or high-pSTAT1 lines (we defined synergy is the equation above >1
or <-1).
MITF binding site analysis
To assess frequency of MITF binding site in gene promoters we used the motif CACATG, known to be a target sequence of MITF. Gene promoters were defined as 5000bp upstream of their transcription start site, or up to the closest upstream gene, whichever is shorter. For each gene, number of binding motif in its promoter sequence was noted.
To assess the significance of number of motif occurrences, we used the binomial distribution. Since the MITF-M and MITF-expression clusters are similar and share genes, for the purpose of this analysis genes were assigned to only one of the clusters based on their NormalGamma score. For each one of the two clusters, MITF-M and MITF-expression, we counted total number of motif occurrences in all the cluster genes.
For simplicity, the expected probability of the motif to randomly appear in a DNA sequence is 2*1/4 6 (6 is the length of the motif, and 2 represent the two strands).
The pvalue of X occurrences is the probability of randomly observing X or more occurrences in a random sequence, or 1-BINOMIAL_CDF(X, N, p), where N is total sequence length and p is 2/4 6 .
For MITF-M cluster, the total promoter sequence is 120735bp, with 83 motif occurrences (59 expected). For MITF-expression cluster, the total promoter sequence is 183399bp, with 86 occurrences (89 expected).
